High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer

To compare the outcome of high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and low-dose-rate brachytherapy (LDR-BT) with or without external beam radiotherapy (EBRT) for localized prostate cancer.

We compared 352 patients treated with HDR-BT as monotherapy (median follow-up time 84 months, NCCN risk classification; low: intermediate: high = 28:145:179) and 486 patients with LDR-BT with or without EBRT (90 months, 194:254:38). HDR-BT treated advanced disease with more hormonal therapy than LDR-BT. LDR-BT excluded patients with T3b-T4 tumor and initial PSA >50 ng/ml. Inverse probability of treatment weighting (IPTW) involving propensity scores was used to reduce background selection bias.

The actuarial 5-year biochemical failure-free survival rates (bNED) were 92.9% and 95.6% (p = 0.25) in the HDR-BT and LDR-BT groups, respectively, and it was 100% and 97.3% (p = 0.99) in the low-risk, 95.6% and 94.3% (p = 0.19) in the intermediate, 89.6% and 94.9% (p = 0.26) in the high-risk groups, and 93.1% and 94.9% (p = 0.98) in selected high-risk group excluding T3b-4 and initial PSA ≥50. IPTW correction also indicated no difference in bNED between LDR-BT and HDR-BT groups. LDR-BT showed a higher incidence of genitourinary (GU) toxicity grade ≥2 than that of HDR-BT in the acute phase and grade 1 toxicity in late phase. Acute GU toxicity grade ≥1 predicted late GU toxicity grade ≥2. External beam radiotherapy plus LDR-BT elevated GI toxicity than LDR-BT only group. Accumulated incidence of late grade ≥2 GU and GU toxicity was equivalent between HDR-BT and LDR-BT. No grade 4 or 5 toxicities were detected in either modality.

HDR-BT monotherapy showed an equivalent outcome to that of LDR-BT with or without EBRT for low-, intermediate- and selected high-risk patients. LDR-BT showed equivalent incidence of grade ≥2 late GI and GU toxicities and higher grade ≥2 acute GU toxicity as that of HDR-BT as a monotherapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018 Nov 08 [Epub ahead of print]

Hideya Yamazaki, Koji Masui, Gen Suzuki, Satoaki Nakamura, Kei Yamada, Koji Okihara, Takumi Shiraishi, Ken Yoshida, Tadayuki Kotsuma, Eiichi Tanaka, Keisuke Otani, Yasuo Yoshioka, Kazuhiko Ogawa

Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan. Electronic address: ., Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan., Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan., Department of Radiation Oncology, National Hospital Organization Osaka National Hospital, Japan., Department of Radiation Oncology, Osaka University Graduate School of Medicine, Japan.